Table 2.

Lifetime risk of gastric and small bowel cancers in Lynch syndrome by pathogenic variant [7,9,10,11,12].

Pathogenic Variant	Affected Individuals, Lifetime Risk	General Population, Lifetime Risk
Gastric Cancer
MLH1	5–7%	0.9%
MSH2 and EPCAM	0.2–9%
MSH6	≤1–7.9%
PMS2	Inadequate data
Small Bowel Cancer
MLH1	0.4–11%	0.3%
MSH2 and EPCAM	1.1–10%
MSH6	≤1–4%
PMS2	0.1–0.3%